U.S. Markets closed
  • S&P 500

    4,574.79
    +8.31 (+0.18%)
     
  • Dow 30

    35,756.88
    +15.73 (+0.04%)
     
  • Nasdaq

    15,235.71
    +9.01 (+0.06%)
     
  • Russell 2000

    2,296.08
    -16.56 (-0.72%)
     
  • Gold

    1,794.30
    -12.50 (-0.69%)
     
  • EUR/USD

    1.1597
    -0.0018 (-0.1508%)
     
  • 10-Yr Bond

    1.6190
    -0.0160 (-0.98%)
     
  • Vix

    15.98
    +0.74 (+4.86%)
     
  • GBP/USD

    1.3766
    -0.0003 (-0.0220%)
     
  • USD/JPY

    114.1810
    +0.4820 (+0.4239%)
     
  • BTC-USD

    60,341.58
    -2,526.57 (-4.02%)
     
  • CMC Crypto 200

    1,498.92
    -6.23 (-0.41%)
     
  • FTSE 100

    7,277.62
    +54.80 (+0.76%)
     
  • Nikkei 225

    29,106.01
    +505.60 (+1.77%)
     

Did Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Insiders Buy Up More Shares?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So shareholders might well want to know whether insiders have been buying or selling shares in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

What Is Insider Selling?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, such insiders must disclose their trading activities, and not trade on inside information.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But logic dictates you should pay some attention to whether insiders are buying or selling shares. For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year'.

View our latest analysis for Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Co-Founder Douglas Fambrough for US$181k worth of shares, at about US$18.06 per share. Even though the purchase was made at a significantly lower price than the recent price (US$36.94), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

Dicerna Pharmaceuticals is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of Dicerna Pharmaceuticals

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Dicerna Pharmaceuticals insiders own 0.2% of the company, worth about US$6.8m. We do generally prefer see higher levels of insider ownership.

So What Does This Data Suggest About Dicerna Pharmaceuticals Insiders?

It doesn't really mean much that no insider has traded Dicerna Pharmaceuticals shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. The transactions are fine but it'd be more encouraging if Dicerna Pharmaceuticals insiders bought more shares in the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. You'd be interested to know, that we found 3 warning signs for Dicerna Pharmaceuticals and we suggest you have a look.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.